1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011.PubMed/NCBI View Article : Google Scholar
|
2
|
Sekido Y, Bader S, Latif F, Chen JY, Duh
FM, Wei MH, Albanesi JP, Lee CC, Lerman MI and Minna JD: Human
semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer
deletion region and demonstrate distinct expression patterns. Proc
Natl Acad Sci USA. 93:4120–4125. 1996.PubMed/NCBI View Article : Google Scholar
|
3
|
Tse C, Xiang RH, Bracht T and Naylor SL:
Human Semaphorin 3B (SEMA3B) located at chromosome 3p21.3
suppresses tumor formation in an adenocarcinoma cell line. Cancer
Res. 62:542–546. 2002.PubMed/NCBI
|
4
|
Castro-Rivera E, Ran S, Thorpe P and Minna
JD: Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast
cancer, whereas VEGF165 antagonizes this effect. Proc Natl Acad Sci
USA. 101:11432–11437. 2004.PubMed/NCBI View Article : Google Scholar
|
5
|
Beuten J, Garcia D, Brand TC, He X, Balic
I, Canby-Hagino E, Troyer DA, Baillargeon J, Hernandez J, Thompson
IM, et al: Semaphorin 3B and 3F single nucleotide polymorphisms are
associated with prostate cancer risk and poor prognosis. J Urol.
182:1614–1620. 2009.PubMed/NCBI View Article : Google Scholar
|
6
|
Pignata A, Ducuing H and Castellani V:
Commissural axon navigation: Control of midline crossing in the
vertebrate spinal cord by the semaphorin 3B signaling. Cell Adhes
Migr. 10:604–617. 2016.PubMed/NCBI View Article : Google Scholar
|
7
|
Shahi P, Wang CY, Chou J, Hagerling C,
Gonzalez Velozo H, Ruderisch A, Yu Y, Lai MD and Werb Z: GATA3
targets semaphorin 3B in mammary epithelial cells to suppress
breast cancer progression and metastasis. Oncogene. 36:5567–5575.
2017.PubMed/NCBI View Article : Google Scholar
|
8
|
Bernatchez PN, Rollin S, Soker S and
Sirois MG: Relative effects of VEGF-A and VEGF-C on endothelial
cell proliferation, migration and PAF synthesis: Role of
neuropilin-1. J Cell Biochem. 85:629–639. 2002.PubMed/NCBI View Article : Google Scholar
|
9
|
Castro-Rivera E, Ran S, Brekken RA and
Minna JD: Semaphorin 3B inhibits the phosphatidylinositol
3-kinase/Akt pathway through neuropilin-1 in lung and breast cancer
cells. Cancer Res. 68:8295–8303. 2008.PubMed/NCBI View Article : Google Scholar
|
10
|
Sabag AD, Smolkin T, Mumblat Y, Ueffing M,
Kessler O, Gloeckner CJ and Neufeld G: The role of the plexin-A2
receptor in Sema3A and Sema3B signal transduction. J Cell Sci.
127:5240–5252. 2014.PubMed/NCBI View Article : Google Scholar
|
11
|
Li G, Gao Y, Ma D and Zhang Z: Downgraded
expression of SEMA3B indicates an unfavorable prognosis in patients
of resectable hepatocellular carcinoma. Int J Clin Exp Pathol.
9:841–853. 2016.
|
12
|
Loginov VI, Dmitriev AA, Senchenko VN,
Pronina IV, Khodyrev DS, Kudryavtseva AV, Krasnov GS, Gerashchenko
GV, Chashchina LI, Kazubskaya TP, et al: Tumor Suppressor Function
of the SEMA3B Gene in Human Lung and Renal Cancers. PLoS One.
10(e0123369)2015.PubMed/NCBI View Article : Google Scholar
|
13
|
Llovet JM and Bruix J: Prospective
validation of the Cancer of the Liver Italian Program (CLIP) score:
A new prognostic system for patients with cirrhosis and
hepatocellular carcinoma. Hepatology. 32:679–680. 2000.PubMed/NCBI View Article : Google Scholar
|
14
|
Lohitesh K, Chowdhury R and Mukherjee S:
Resistance a major hindrance to chemotherapy in hepatocellular
carcinoma: An insight. Cancer Cell Int. 18(44)2018.PubMed/NCBI View Article : Google Scholar
|
15
|
Braga EA, Kashuba VI, Maliukova AV,
Loginov VI, Senchenko VN, Bazov IV, Kiselev LL and Zabarovskiĭ ER:
New tumor suppressor genes in hot spots of human chromosome 3: New
methods of identification. Mol Biol (Mosk). 37:194–211.
2003.PubMed/NCBI(In Russian).
|
16
|
Falk J, Bechara A, Fiore R, Nawabi H, Zhou
H, Hoyo-Becerra C, Bozon M, Rougon G, Grumet M, Püschel AW, et al:
Dual functional activity of semaphorin 3B is required for
positioning the anterior commissure. Neuron. 48:63–75.
2005.PubMed/NCBI View Article : Google Scholar
|
17
|
Tischoff I, Markwarth A, Witzigmann H,
Uhlmann D, Hauss J, Mirmohammadsadegh A, Wittekind C, Hengge UR and
Tannapfel A: Allele loss and epigenetic inactivation of 3p21.3 in
malignant liver tumors. Int J Cancer. 115:684–689. 2005.PubMed/NCBI View Article : Google Scholar
|
18
|
Chen R, Zhuge X, Huang Z, Lu D, Ye X, Chen
C, Yu J and Lu G: Analysis of SEMA3B methylation and expression
patterns in gastric cancer tissue and cell lines. Oncol Rep.
31:1211–1218. 2014.PubMed/NCBI View Article : Google Scholar
|
19
|
Ochi K, Mori T, Toyama Y, Nakamura Y and
Arakawa H: Identification of semaphorin3B as a direct target of
p53. Neoplasia. 4:82–87. 2002.PubMed/NCBI View Article : Google Scholar
|
20
|
Neufeld G, Lange T, Varshavsky A and
Kessler O: Semaphorin signaling in vascular and tumor biology. Adv
Exp Med Biol. 600:118–131. 2007.PubMed/NCBI View Article : Google Scholar
|
21
|
Halbersztadt A, Haloń A, Pajak J,
Robaczyński J, Rabczynski J and St Gabryś M: The role of matrix
metalloproteinases in tumor invasion and metastasis. Ginekol Pol.
77:63–71. 2006.PubMed/NCBI(In Polish).
|
22
|
Patel S, Sumitra G, Koner BC and Saxena A:
Role of serum matrix metalloproteinase-2 and -9 to predict breast
cancer progression. Clin Biochem. 44:869–872. 2011.PubMed/NCBI View Article : Google Scholar
|
23
|
Zhu H, Zhai B, He C, Li Z, Gao H, Niu Z,
Jiang X, Lu J and Sun X: LncRNA TTN-AS1 promotes the progression of
cholangiocarcinoma via the miR-320a/neuropilin-1 axis. Cell Death
Dis. 11(637)2020.PubMed/NCBI View Article : Google Scholar
|
24
|
Gao Y: Expression of Semaphorin-3B,
Vascular endothelial growth factor,and their common receptor
Neuropilin-1 inHepatocellular carcinoma. China Doctoral Thesis
Library 04, 2014.
|
25
|
Huang YH, Chen CH, Chang TT, Chen SC, Wang
SY, Lee HS, Lin PW, Huang GT, Sheu JC, Tsai HM, et al: Evaluation
of predictive value of CLIP, Okuda, TNM and JIS staging systems for
hepatocellular carcinoma patients undergoing surgery. J
Gastroenterol Hepatol. 20:765–771. 2005.PubMed/NCBI View Article : Google Scholar
|
26
|
Cai G, Qiao S and Chen K: Suppression of
miR-221 inhibits glioma cells proliferation and invasion via
targeting SEMA3B. Biol Res. 48(37)2015.PubMed/NCBI View Article : Google Scholar
|
27
|
Tang H, Wu Y, Liu M, Qin Y, Wang H, Wang
L, Li S, Zhu H, He Z, Luo J, et al: SEMA3B improves the survival of
patients with esophageal squamous cell carcinoma by upregulating
p53 and p21. Oncol Rep. 36:900–908. 2016.PubMed/NCBI View Article : Google Scholar
|